REG - SolGold PLC - Quarterly MD&A Filed in Canada

SolGoldAnnouncement

15/05/2019 07:05

RNS Number : 0175Z
SolGold PLC
15 May 2019
 


15 May 2019
 
SolGold plc
("SolGold" or the "Company")
 
Quarterly MD&A Filed in Canada
 
 
The Board of SolGold (LSE and TSX code: SOLG) is pleased to advise all shareholders and interested investors that the Company's website contains access to a copy of the Quarterly Financial and Management Discussion and Analysis ("MD&A") required to be filed on Sedar in Canada, in connection with the Company's quarterly financial period ended 31 March 2019.  This additional information is available in the Financial Reports section of the Investor Centre on the Company's website: www.solgold.com.au
 
By order of the Board
Karl Schlobohm
Company Secretary
 
References to figures and tables relate to the version visible in PDF format by clicking the link below:
http://www.rns-pdf.londonstockexchange.com/rns/0175Z_1-2019-5-14.pdf
 
CONTACTS
 




Nicholas Mather
SolGold Plc (Chief Executive Officer) nmather@solgold.com.au
 


Tel: +61 (0) 7 3303 0665
+61 (0) 417 880 448




Karl Schlobohm
SolGold Plc (Company Secretary) kschlobohm@solgold.com.au
 


Tel: +61 (0) 7 3303 0661




Anna Legge
SolGold Plc (Corporate Communications) alegge@solgold.com.au
 


Tel: +44 (0) 20 3823 2131




Gordon Poole / Nick Hennis Camarco (Financial PR / IR) solgold@camarco.co.uk
 


Tel: +44 (0) 20 3757 4997




Andrew Chubb / Ingo Hofmaier
Hannam & Partners (Joint Broker and Financial Advisor)
solgold@hannam.partners
 


Tel: +44 (0) 20 7907 8500




Ross Allister / David McKeown
Peel Hunt (Joint Broker and Financial Advisor)
solgold@peelhunt.com
 


Tel: +44 (0)20 7418 8900




James Kofman / Darren Wallace
Cormark Securities Inc. (Financial Advisor)
dwallace@cormark.com 
 


Tel: +1 416 943 6411




 
Follow us on twitter @SolGold_plc




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCUSRVRKVAVAAR